Results: All five cases were diagnosed based on biopsies indicating increased serum levels of creatinine. Proteinuria status varied from negative to 2+. The median period from transplantation to allograft biopsy was 4068 days. Four of the five cases exhibited suspicious antibody-mediated rejection together with dnMN. The glomerular capillaries of all cases were C4d-positive, as were the peritubular capillaries of three of the four ABOcompatible transplants. In terms of IgG subclass, IgG1 and IgG3 predominated in all cases, and phospholipase A2 receptor status (evaluated via immunoreactivity) was negative in all cases. We examined two cases by immunoelectron microscopy using anti-IgG and anti-C4d antibodies. We found subendothelial and intramembranous deposits expressing both IgG and C4d, corresponding to positivity in immunofluorescence analysis.
Conclusion:
We confirmed the existence of dnMN stage 0 by focusing on granular IgG immunofluorescence positivity.
De novo membranous nephropathy (dnMN) is a newly recognized complication of post-transplantation patients in whom membranous nephropathy (MN) was not the disease that triggered end-stage renal failure (ESRF). DnMN affects about 2% of kidney allograft patients; the percentage is 9% in paediatric patients. 1 DnMN tends to occur later than recurrent membranous nephropathy (rMN) (medians: dnMN, 49.3 months; rMN, 15.6 months; P < 0.05). 2 A previous report indicated that about 50% of grafts that develop dnMN eventually failed. 3 Therefore, dnMN is a serious complication in kidney recipients.
DnMN tissue generally does not stain for the phospholipase A2 receptor (PLA2R), and in terms of the IgG subclass profile, IgG1 predominates (IgG1 > IgG4) in immune deposits, in contrast to the situation in idiopathic MN (iMN)/ rMN. 4, 5 In other words, dnMN may differ immunologically from iMN/rMN; the immunoreactivity patterns of PLA2R and the IgG subclass are distinct. Previous studies have suggested that dnMN is associated with antibody-mediated rejection (ABMR); in addition, dnMN may develop in conjunction with other renal diseases, including ureteral obstruction, renal infarction, and recurrent IgA nephropathy.
6-8
Some patients with early-stage rMN exhibit immunofluorescent evidence of disease before immune complex (IC) deposition is visible via electron microscopy (EM). These cases are termed 'stage 0' rMN, 9 and treatment has been quite effective in terms of clinical remission and histological resolution. 10 Early diagnosis and treatment of dnMN also can improve graft survival but little has been reported on early stage dnMN. As allograft biopsy including perprotocol examinations can detect early stage dnMN, we searched for 'dnMN stage 0,' which we defined pathologically as described below, and studied the clinicopathological features.
METHODS
We for 5-10 min and then washed them in 0.1 M PB. Next, we incubated the sections with 1% (w/v) osmium tetroxide in 1.0 M PB for 60 min, washed them in PB, and then subjected them to dehydration in a series of graded alcohol baths. The samples were embedded in epoxy resin using the inverted capsule method. After thermal polymerization, the sections were stained with lead and uranium and subjected to EM. Samples that were not treated with primary antibodies served as negative controls. We collected clinical data from medical records.
RESULTS

Patient characteristics
We analyzed five dnMN cases (Table 1) , of whom three were male. The median age at transplantation was 31 years old (range 20-69 years). The original conditions triggering ESRF were a hypoplastic kidney, IgA nephropathy, vesicoureteral reflux (VUR), and diabetic nephropathy; only Case 1 had a condition of unknown aetiology. Living related donors gave kidneys to four of the five cases. Four cases were ABO-compatible transplantations. Donor-specific antibody (DSA) was evident only in Case 2 after transplantation, and was PRA class II de novo DSA. The median time to dnMN diagnosis after transplantation was 4068 days (range 251-6031 days). All cases were diagnosed based on biopsies indicating increased serum levels of creatinine (median 1.66 mg/dL; range 0.6-4.21 mg/dL). Urine protein status varied (from negative to strongly positive [2+]) upon dipstick examination; no cases exhibited proteinuria in the nephrotic range. Allograft and patient prognostic data were available for three cases (1, 4, and 5; Table 1 ). Two allografts were lost to suspicious ABMR (Case 4) and one case was lost to death with a functional graft (DWFG) (Case 5) at 2 and 9 years after transplantation, respectively. Case 4 did not comply with the immunosuppressant regime.
Light microscopy
Case 1 exhibited minor glomerular abnormalities ( Table 2) . The other four cases had concurrent ABMR features. Cases 2, 3, and 4 exhibited transplant glomerulopathy (TGP) (Fig. 1A) . Case 5 had both transplant glomerulitis and peritubular capillaritis. No GBM changes indicative of MN were apparent in any cases.
Immunofluorescence examination
All five cases exhibited granular IgG and C4d immunoreactivity of the GCs (Table 2 , Fig. 1C,D) . Three of the four ABO-compatible cases were immunoreactive for C4d along the peritubular capillaries (Fig. 1B) . Cases 2 and 3 exhibited mesangial IgA deposition. Case 2 was diagnosed with de novo IgA nephropathy and Case 3 later developed recurrent IgA nephropathy. Two cases (3 and 4) were positive for C1q (both mesangially and peripherally). Tubular epithelial cells (TECs) were immunoreactive for HLA-DR in three of the five cases. The IgG subclass was predominantly IgG1 or IgG3 (not IgG4) in all four cases examined. No PLA2R immunoreactivity was evident in any of the four cases examined.
Electron microscopy
Electron microscopy revealed focal and segmental FPE of the GBM (Fig. 2A) . The FPE of dnMN stage 0 was more focal than that of MCNS. In terms of the FPE, the extent of foot process material was comparable between dnMN stage 0 and MCNS cases. We also recorded sparse dense microinvagination. Although we initially thought that dense microinvagination might be characteristic of early dnMN stage 0, the zero-hour biopsy specimens of paediatric allografts exhibited very similar findings. Therefore, we currently regard dense microinvagination as a nonspecific GBM reaction. In two cases (4 and 5), follow-up biopsy revealed obvious dense intramembranous deposits, which suggest dnMN progression (Fig. 2B ). These deposits were localized to the focal and segmental regions in both cases.
Immunoelectron microscopy
We used pre-embedding iEM to detect C4d and IgG (using the peroxidase-labelled antibody method) in Cases 1 (Fig. 3A-C ) and 5 (data not shown). Both cases were positive for both proteins, which were scattered throughout the subendothelial and intramembranous regions, consistent with the IF findings. Case 1 (with minor glomerular abnormalities evident via LM) exhibited C4d and IgG depositions in the subendothelial and intramembranous regions (C4d: Fig. 3A , IgG: Fig. 3C ). When the primary anti-C4d antibody was omitted, the lesions were isodense with the GBM, and thus difficult to detect (Fig. 3B ). Case 5, who exhibited suspicious acute ABMR via LM, also had subendothelial and intramembranous deposits of C4d and IgG. We also used iEM to detect IgG ( Fig. 3D and E 
DISCUSSION
We investigated the early stages of dnMN (dnMN stage 0) after allograft kidney transplantation. DnMN developed in 9 The clinical and pathological features of early stage rMN included relatively severe proteinuria (sometimes in the nephrotic range; mean 1129 mg/day; range 0-5780 mg/ day), little variation in creatinine levels (range 0.8-2.8 mg/ dL), and no apparent glomerular or peritubular changes noted via LM in patients without deposits evident on LM or GBM spikes. 9 These results support the idea that ABMR is 
(c/i), ABO-compatible/incompatible transplants; aABMR, acute antibody-mediated rejection; Bx, kidney biopsy; cABMR, chronic antibody-mediated rejection; cg, transplant glomerulopathy; g, transplant glomerulitis; GC, glomerular capillary; HLA-DR, human leukocyte antibody-DR (immunoreactivity on tubular epithelial cell); LM, light micrograph. MGA, minor glomerular abnormalities; m, mesangial; n.a., not available; p, peripheral; PLA2R, M type phospholipase A2 receptor; ptc, peritubular capillaritis; ptc, peritubular capillary; ptcbm, transplant capillaropathy (score from Banff 2013). strongly associated with the development of very early dnMN. In fact, previous studies have found that ABMR can proceed to dnMN. Honda et al. reported 17 cases of dnMN and compared them with controls. 6 Histological features of ABMR were much more common in dnMN than control samples; for example, the incidence of peritubular capillaritis was 82.4% in dnMN and 41.2% in control samples (P = 0.001); other histological findings (glomerulitis, TGP, C4d immunoreactivity, and thickening of the PTCBM) exhibited similar tendencies. Furthermore, all five recipients examined using FCXM or PRA expressed DSAs at the time of biopsy, which indicates a strong association between dnMN and ABMR. 6 In addition, the PLA2R status of all of our dnMN stage 0 cases was negative. Debiec et al. found that no dnMN patients biopsied expressed PLA2R; 5 of 10 rMN patients did, 11 which suggests that our dnMN stage 0 cases were similar to the relatively progressive dnMN cases previously reported. We explored differences between the IgG subclass and complement components expressed by dnMN and iMN/rMN patients. Segawa et al. reported that iMN was associated with IgG4-predominant immunoreactivity (in terms of the IgG subclass) and expression of mannose-binding lectin (MBL), a component of the lectin pathway.
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Many previous reports on dnMN have suggested that the condition is associated with ABMR developing after kidney transplantation, although the details remain unclear. Using iEM, we found IgG and C4d deposits in the subendothelial A B and intramembranous regions but not the subepithelial region, corresponding to the IF findings. Omission of primary antibody rendered it difficult to detect these deposits, which may explain why no dense deposits were apparent via routine EM. We hypothesize that dnMN commences in the subendothelial and intramembranous regions, and rMN commences with a dense subepithelial deposit, 9 for the following reasons. First, dnMN and rMN are completely different in terms of immunological features and pathogenesis. 4 Therefore, the relevant antigens and antibodies differ. Second, dnMN is supposed to be associated with ABMR, 6 which suggests that its pathogenesis might feature antigenantibody reactions around endothelial cells that express HLA. 13, 14 Thus, it is reasonable that early lesions of dnMN develop in the subendothelial and intramembranous areas. Previous studies (using animal models) have reported intraglomerular basement membrane translocation of immune complexes (ICs) from the subendothelial to the subepithelial region in animals with passive in situ IC nephritis. 15 Thus, it is possible that ICs produced in subendothelial lesions via ABMR may become incorporated into the GBM. Further work is needed. We found that, pathologically, dnMN progressed, as did the ABMR findings, compromising graft function associated with elevated serum creatinine levels in two of the five cases (40%). This suggests that dnMN progresses from dnMN stage 0. Such a tendency has also been reported in a previous study on rMN patients; in that study, pathological progression was characterized by subepithelial electron-dense deposits evident via EM in 11 of 16 recipients diagnosed with early stage rMN, similar to what we found with dnMN stage 0 patients. 9 The prognosis of dnMN remains obscure. In our study, excluding the DWFG case, one of the three cases for whom prognostic information was available lost his allograft to suspicious CABMR. Truong et al. showed that 6 of 10 dnMN cases lost their allografts at 3 years (on average) after diagnosis. 3 Schwarz et al. found that the 5-year graft survival rate did not differ significantly between 21 dnMN cases and 851 other renal transplant recipients (71.4 AE 9.9% vs. 60.8 AE 2.2% after 5 years). 16 Similarly, Honda et al.
reported similar allograft loss rates in 17 dnMN and 17 control cases (17.6% vs. 23.5%, respectively). 6 Thus, the deterioration of graft function associated with dnMN may not be attributable to dnMN per se, but rather to concurrent disease and developments including antibody-mediated rejection, which is a well-known risk factor for graft loss. 14 Therefore, early dnMN diagnosis would encourage exploration for a concomitant disease or condition associated with poor graft outcomes. GC-positivity for IgG and C4d on per-protocol/ induction biopsy scheduled at an appropriate time would allow early and precise dnMN detection. The natural course of dnMN and the advantages and disadvantages of early intervention are issues that require further research in the future.
Our work had certain limitations. This was a retrospective study with a small sample size, and we lacked data on DSA and long-term prognoses. We did not compare the clinical and pathological findings of dnMN and rMN.
In conclusion, we identified dnMN stage 0 (with granules immunoreactive for IgG in terms of IF but lacking dense deposits via EM). The diagnosis of MN detectable by IF only (dnMN), followed by appropriate intervention, could improve graft survival.
